Shree Ganesh Remedies Ltd

AI
Shree Ganesh Rem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Shree Ganesh Remedies Ltd

₹ 650 -5.88%
21 Oct - close price
ganeshremedies.com BSE: 540737 NSE: SGRL
About

Shree Ganesh Remedies is an Ankleshwar-based manufacturer of pharmaceutical/API intermediates and specialty and fine chemicals. It also provides custom synthesis and contract manufacturing for pharmaceutical, agrochemical, polymer, and electronics customers across more than 20 countries.[1] [2]

Key Points

Business model
The company is transitioning from generic and off-patent pharmaceutical intermediates towards patented, customer-specific molecules and CRAMS/CDMO assignments. Its services span process and route development, pilot production, technology transfer and commercial manufacturing. [1] [2]

Website BSE NSE
  • Market Cap ₹ 832 Cr.
  • Current Price ₹ 650
  • High / Low ₹ 759 / 381
  • Stock P/E 53.9
  • Book Value ₹ 127
  • Dividend Yield 0.00 %
  • ROCE 14.1 %
  • ROE 10.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Debtor days have increased from 80.8 to 109 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2021 Sep 2021 Dec 2021 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
12.63 16.97 21.13 37.33 24.78 32.33 27.05 24.43 24.67 30.32 21.11 33.20 14.36
9.58 12.52 15.36 20.39 16.65 21.02 17.14 14.55 17.37 20.70 14.38 21.82 11.01
Operating Profit 3.05 4.45 5.77 16.94 8.13 11.31 9.91 9.88 7.30 9.62 6.73 11.38 3.35
OPM % 24.15% 26.22% 27.31% 45.38% 32.81% 34.98% 36.64% 40.44% 29.59% 31.73% 31.88% 34.28% 23.33%
1.11 0.44 0.88 1.32 0.54 0.19 0.71 2.29 0.66 0.69 0.66 1.02 0.94
Interest 0.07 0.03 0.03 0.15 0.32 0.44 0.39 0.97 0.94 1.01 0.74 0.88 0.32
Depreciation 0.82 0.95 0.99 1.86 2.02 2.42 2.70 2.42 2.42 2.59 2.67 2.80 2.44
Profit before tax 3.27 3.91 5.63 16.25 6.33 8.64 7.53 8.78 4.60 6.71 3.98 8.72 1.53
Tax % 28.75% 22.76% 25.40% 22.46% 26.70% 25.81% 27.89% 24.83% 25.00% 26.23% 22.36% 28.21% 27.45%
2.34 3.02 4.20 12.59 4.65 6.41 5.42 6.59 3.45 4.96 3.09 6.27 1.12
EPS in Rs 1.83 2.36 3.28 9.84 3.62 4.99 4.22 5.13 2.69 3.86 2.41 4.88 0.87
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025 Mar 2026 TTM
35 64 49 126 109 109 99
26 52 35 84 69 74 68
Operating Profit 9 13 14 42 39 35 31
OPM % 25% 20% 28% 33% 36% 32% 31%
1 4 2 3 4 3 3
Interest 0 1 0 1 2 4 3
Depreciation 1 2 3 6 10 10 10
Profit before tax 9 14 13 38 31 24 21
Tax % 28% 23% 25% 26% 26% 26%
6 10 10 28 23 18 15
EPS in Rs 4.88 8.18 7.62 21.96 17.97 13.83 12.02
Dividend Payout % 18% 13% 18% 2% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 17%
3 Years: %
TTM: -9%
Compounded Profit Growth
10 Years: %
5 Years: 11%
3 Years: %
TTM: -29%
Stock Price CAGR
10 Years: %
5 Years: 13%
3 Years: 11%
1 Year: 32%
Return on Equity
10 Years: %
5 Years: %
3 Years: 16%
Last Year: 11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025 Mar 2026
Equity Capital 9 9 13 13 13
Reserves 25 33 109 132 150
1 4 36 38 31
7 9 12 8 14
Total Liabilities 41 55 171 192 208
14 20 81 95 105
CWIP 0 0 17 9 13
Investments 4 3 5 18 13
23 32 69 70 78
Total Assets 41 55 171 192 208

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025 Mar 2026
-5 5 3 30 31 24
-0 -3 -1 -33 -35 -9
-0 -0 -1 10 -1 -12
Net Cash Flow -5 1 2 7 -6 3
Free Cash Flow -5 5 3 -1 7 7
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -60% 37% 24% 92% 104% 82%

Ratios

Consolidated / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025 Mar 2026
Debtor Days 101 101 59 75 109
Inventory Days 125 61 156 223 209
Days Payable 75 43 51 61 82
Cash Conversion Cycle 151 119 164 238 236
Working Capital Days 145 103 89 111 128
ROCE % 35% 19% 14%

Insights

In beta
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Export Revenue (FOB Value)
Rs. Crores

Log in to view insights

Please log in to see hidden values.

Login
Total Permanent Employees
count
Pilot Plant Reactors
count
Functional Production Blocks (Unit 1)
count
Number of Countries Served
count
R&D and Process Team Size
count
Total Production Reactors
count
Specialty Chemicals Revenue
Rs. Crores

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
69.33% 69.33% 69.33% 70.49% 72.80% 72.80% 72.80% 72.80% 72.80% 72.83% 72.83% 72.83%
0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.52% 0.99%
30.66% 30.67% 30.66% 29.50% 27.19% 27.20% 27.20% 27.19% 27.20% 27.16% 26.65% 26.17%
No. of Shareholders 7,5187,0497,1868,5088,6958,9789,1668,7528,4428,0587,8228,234

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls